Rapamycin for treatment of tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: report of two cases and review of literature / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 684-687, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-862905
ABSTRACT
Objective:
To investigate the effect of rapamycin in treatment of tyrosine kinase inhibitor (TKI)-resistant chronic myelogenous leukemia (CML) without ABL mutation.Methods:
Flow cytometry was used to detect the positive expressions of p-mTOR and p-S6 in CD33 positive cells of 2 CML patients with TKI resistance in Jiangsu Province Hospital, and the influence of rapamycin on the positive expressions of p-mTOR and p-S6 in vitro.Results:
Rapamycin in vitro inhibited the positive expressions of p-mTOR and p-S6 in CD33 positive cells. After 3 months of oral administration of rapamycin, the positive expressions of p-mTOR and p-S6 in CD33 positive cells were decreased, and the copy number of BCR-ABL fusion gene was also decreased simultaneously.Conclusion:
Part of the resistance of CML patients to TKI may be related to the activation of intracellular signaling pathway of mTOR.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS